The split is mostly one enzyme. Minoxidil is inert until a scalp enzyme, sulfotransferase, activates it, and that enzyme varies about ten-fold between people 1. That's most of why four in ten respond and not nine in ten. It also doesn't touch the hormone driving the loss, so it holds the clock back from the far end rather than stopping it.
On responders the effect is real and measured. The men's pivotal trial gained about 19 hairs per square centimetre at 5% by week 48, against 4 on placebo 2. Generic foam costs $10–15 a month. The oral pill works about as well and is broadly safe 3.
Pick topical or oral, then hold the line for a year.
The arc, and the string attached.
- Weeks 2–8: more hair in the drain. This is the "dread shed," and it's where most people quit. Wait.
- Months 3–4: shedding stops, fine downy regrowth in the temples or crown.
- Months 6–12: on responders, clear density change on photos. Peak effect.
- Years: you keep what you grew only while you keep applying it.
Stop after five years and the regrowth is gone within three months, plus the loss that was happening underneath — hair counts drop back to baseline, sometimes below it 6. This is a commitment, not a course.
The fine print — when to skip it, and what people get wrong
The foam isn't weaker than the solution — same drug, same 5%, different carrier 7. And when stopping "causes" loss, it didn't: it just reveals the loss that never paused.
Non-response is usually low scalp enzyme activity; switch to oral or add microneedling 5. Starting a decade late leaves too few live follicles. Daily aspirin blunts the topical too 1.
Skip during pregnancy or breastfeeding. For oral, avoid with heart disease, untreated arrhythmia, or kidney impairment, and buy from a regulated pharmacy — the rare heart complications trace to compounding dose errors 8.
- 1Goren et al. (2014). Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. link
- 2Olsen et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. link
- 3Sobral et al. (2025). Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. International Journal of Dermatology. link
- 4Suchonwanit et al. (2018). A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. International Journal of Dermatology. link
- 5Dhurat R, Sharma A (2017). A novel cosmetic approach to treat thinning hair. British Journal of Dermatology. link
- 6Olsen EA, Weiner MS, Delong ER, Pinnell SR (1987). Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. Journal of the American Academy of Dermatology. link
- 7Friedman et al. (2002). Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. Journal of the American Academy of Dermatology. link
- 8Randolph M, Tosti A (2021). Oral minoxidil treatment for hair loss: a review of efficacy and safety. Journal of the American Academy of Dermatology. link
დაკავშირებული სახელმძღვანელოში (6)
- — If minoxidil regrowth has stalled, weekly scalp microneedling can multiply its effect — it's built to be paired with it.
- — Minoxidil is the other pillar of hair-loss treatment, and combining it with finasteride beats either alone.
- — Before a transplant, minoxidil is the first, reversible step — and most transplant patients stay on it to protect the rest.
- — Adding microneedling to minoxidil markedly boosts regrowth versus the drug alone.
- — For early hair thinning, red light is one of the few add-ons with real evidence — often stacked on top of minoxidil.
- — For thinning hair, saw palmetto is at best a weak add-on; minoxidil is half the proven standard stack.
Minoxidil
FDA-approved 1988 for men, 1991 for women. Hundreds of RCTs over 35+ years, including pivotal Olsen 2002 (n=393, men) and Bergfeld 2016 (n=404, women); multiple Cochrane-grade meta-analyses; 2023 Bayesian NMA places topical 5% as the strongest FDA-approved topical monotherapy. LDOM has accumulated four RCTs and a 1404-patient multicenter safety series (Vañó-Galván 2021). Mechanism (SULT1A1 → K_ATP) is biochemically characterised (Shorter 2008).
Generic 5% topical foam runs ~$10–15/month ($120–180/year); generic 5% solution ~$5–10/month ($60–120/year). Compounded LDOM at 2.5 mg/day runs $30–60/month from US pharmacies, <$5/month from generic-tablet markets. Annual spend sits in the $50–500 minor-burden band; lifelong commitment compounds it.
Topical: twice-daily application to dry scalp, 1–2 minutes per dose, indefinite duration. Wet-hair and styling friction in the morning is the dominant adherence barrier. Once-daily 5% foam reduces but does not eliminate friction; LDOM converts the burden to a single daily tablet. Lifelong cadence with no defined endpoint.
Topical 5% produces a mean +18.6 non-vellus hairs/cm² over 48 weeks vs +3.9 on placebo in the pivotal Olsen 2002 RCT; female-pattern data (Bergfeld 2016) shows photographically visible density change by 24 weeks. Roughly 40% of users get clinically meaningful regrowth; another 30% see stabilisation. Effect appears at 3–6 months, not days — short of a 4 — but consistently noticed by others on responders.
Continuous use over 1–10 years compounds against the otherwise-progressive AGA miniaturisation curve; this is the entire long-game premise of the drug. Score capped at 3 because (i) ~40% of users never respond meaningfully (SULT1A1-dependent), (ii) discontinuation resets within 3–6 months to the underlying trajectory (Olsen 1987), and (iii) trial data past 5 years is observational.
Indirect effect mediated by appearance change. Quality-of-life literature on AGA documents modest depression-symptom and self-esteem decrements (larger in women), and successful regrowth reverses a fraction of these. Effect is real but second-order and conditional on responder status — not the reason to take it.